J Clin Aesthet Dermatol. 2019;12(12):28–34 by Corinna E. Psomadakis, MBBS, and George Han, MD Drs. Psomadakis and Han are with the Department of Dermatology, Mount Sinai Medical Center in New
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis,